Drugs / CP101
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05852574 | Sep 2023 → Nov 2024 overdue | ulcerative colitis | Brigham and Women's Hospital | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03829878 | May 2020 | autism | Finch Research and Development LLC. | Withdrawn | No outcome recorded |
| Phase 2 | NCT03497806 | May 2018 → Dec 2020 | CADINS disease, Clostridium difficile colitis, familial mesial temporal lobe epilepsy | Finch Research and Development LLC. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05153499 Comparator | Nov 2021 → Feb 2023 | Clostridium difficile colitis | Finch Research and Development LLC. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CP101 | “CP101 is an investigational oral microbiome drug designed to deliver a complete and functional microbiome to durably repair intestinal dysbiosis, which is being evaluated for...” NCT05852574 ↗ |
| Modality | Other / unclassified | “CP101 (Full-Spectrum Microbiota®)” NCT03829878 ↗ |
| Route | Oral | “Study drug will be administered at Treatment (Day 1) as an oral dose” NCT03497806 ↗ |